Adverse Events of Lutetium-177-PSMA-617 Revealed
Lutetium-177-PSMA-617 (Pluvicto®) has emerged as a groundbreaking radiolabeled therapeutic agent in the battle against advanced prostate cancer, specifically targeting metastatic ...
Lutetium-177-PSMA-617 (Pluvicto®) has emerged as a groundbreaking radiolabeled therapeutic agent in the battle against advanced prostate cancer, specifically targeting metastatic ...
In recent years, chimeric antigen receptor T-cell therapy, commonly known as CAR-T therapy, has revolutionized the field of oncology, offering ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine